Risk of Serious Infection With Adalimumab in Hidradenitis Suppurativa Compared With Psoriasis

Is the risk of serious infection different between adalimumab users with hidradenitis suppurativa (HS) and psoriasis?In this cohort study of 10 349 new adalimumab users, including 1650 with HS and 8699 with psoriasis, the risk of hospitalization due to noncutaneous infections was higher in those with HS, even after adjusting for confounders. Additionally, patients with HS also had a greater likelihood of developing sepsis and genitourinary infections.These results underscore the need for strategies to reduce the infection risk in the HS population.

Corresponding Author: Bruna Galvao de Oliveira Wafae, MD, MMSc, Department of Dermatology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215 (bgalvaod@bidmc.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.